CAR-T Therapy for Non-Hodgkin's Lymphoma
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment where a patient's own immune cells are modified to better attack their cancer. It is for adults with a type of lymphoma that hasn't responded to other treatments. The modified cells target specific proteins on the cancer cells to help the immune system destroy them. This new method enhances the patient's immune cells to find and eliminate cancer cells.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What safety data exists for CAR-T therapy in humans?
CAR T-cell therapies, like those targeting CD19 for non-Hodgkin lymphoma, can cause side effects such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), which may affect the brain and nervous system. These side effects are known complications and require careful management.12345
What makes the treatment C-CAR039 unique for Non-Hodgkin's Lymphoma?
C-CAR039 is a novel CAR-T cell therapy that targets both CD19 and CD20 proteins on B-cells, unlike other CAR-T therapies that typically target only CD19. This dual targeting may enhance its effectiveness in treating Non-Hodgkin's Lymphoma by potentially overcoming resistance seen in single-target therapies.678910
What data supports the effectiveness of the treatment C-CAR039 for Non-Hodgkin's Lymphoma?
The effectiveness of C-CAR039, a CAR-T therapy, can be indirectly supported by studies on similar treatments like axicabtagene ciloleucel and tisagenlecleucel, which have shown promising results in treating relapsed or refractory large B-cell lymphoma, a type of Non-Hodgkin's Lymphoma. These therapies have demonstrated durable responses in patients who had limited options, suggesting potential benefits for C-CAR039 as well.1011121314
Who Is on the Research Team?
Janssen Research & Development, LLC Clinical Trial
Principal Investigator
Janssen Research & Development, LLC
Are You a Good Fit for This Trial?
Adults with B-Cell non-Hodgkin lymphoma that has come back or didn't respond after at least two standard treatments can join. They must be over 18, have a certain level of physical fitness (ECOG status 0 or 1), and their major organs need to function well. People with recent serious blood clots, active severe infections, other cancers within the last five years (except some skin or in situ cancers), pregnant women, and those with certain heart conditions cannot participate.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive an intravenous infusion of autologous JNJ-90014496 on Day 1
Follow-up
Participants are monitored for safety, effectiveness, and pharmacokinetics after treatment
Long-term follow-up
Participants are monitored for overall survival and progression-free survival
What Are the Treatments Tested in This Trial?
Interventions
- C-CAR039
C-CAR039 is already approved in United States, China for the following indications:
- Relapsed or refractory B-cell non-Hodgkin lymphoma (r/r B-NHL)
- Follicular lymphoma
- Relapsed or refractory B-cell non-Hodgkin lymphoma (r/r B-NHL)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Janssen Research & Development, LLC
Lead Sponsor
Joaquin Duato
Janssen Research & Development, LLC
Chief Executive Officer since 2022
MBA from ESADE, Master of International Management from Thunderbird School of Global Management
Dr. Jijo James, MD
Janssen Research & Development, LLC
Chief Medical Officer since 2014
MD from St. Johns Medical College, MPH from Columbia University
Cellular Biomedicine Group Ltd.
Lead Sponsor
Cellular Biomedicine Group, Inc.
Lead Sponsor
City of Hope Medical Center
Collaborator